Related Experiment Video

Updated: Feb 1, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.7K

Nilotinib in the treatment of chronic myeloid leukemia

Tomasz Sacha1, Giuseppe Saglio2

  • 1Department of Hematology, Jagiellonian University Hospital, ul. Kopernika 17, 31-501 Kraków, Poland.

Future Oncology (London, England)
|December 15, 2018
PubMed

Insights

Nilotinib offers faster, deeper molecular responses in newly diagnosed chronic myeloid leukemia (CML) compared to imatinib. Achieving sustained deep molecular response may allow for treatment-free remission in some CML patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Hematology

Background:

  • Imatinib resistance in chronic myeloid leukemia (CML) is a significant clinical challenge.
  • Nilotinib, a second-generation tyrosine kinase inhibitor, was developed to address imatinib resistance.
  • First-line treatment with nilotinib shows promise in newly diagnosed CML patients.

Purpose of the Study:

  • To evaluate the efficacy of nilotinib in first-line treatment of newly diagnosed chronic myeloid leukemia (CML).
  • To discuss the role of nilotinib in achieving optimal treatment endpoints, including treatment-free remission.
  • To review the pharmacologic properties of nilotinib and its implications for CML management.

Main Methods:

  • Review of clinical data on nilotinib in first-line CML treatment.
  • Analysis of molecular response rates compared to imatinib.
  • Discussion of treatment discontinuation trials and durable treatment-free remission.

Main Results:

  • Nilotinib induces faster and deeper molecular responses in a higher percentage of newly diagnosed CML patients than imatinib.
  • Treatment-free remission is an emerging goal for a subset of CML patients.
  • Nilotinib demonstrates favorable pharmacologic properties for CML management.

Conclusions:

  • Nilotinib is an effective first-line treatment for newly diagnosed CML, offering superior molecular responses.
  • Achieving sustained deep molecular response with nilotinib opens possibilities for treatment discontinuation and durable remission.
  • Nilotinib represents a significant advancement in the management of chronic myeloid leukemia.
Keywords:
BCR-ABLCMLPh-chromosomenilotinib

More Related Videos

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.5K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.9K

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.0K
Chronic Pharyngitis01:23

Chronic Pharyngitis

Chronic pharyngitis refers to persistent inflammation of the pharyngial mucosa.
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
11.9K
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
740
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
996
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
802